Pharmaceutical care of a case of hepatitis B virus reactivation induced by iparomlimab and tuvonralimab
- VernacularTitle:艾帕洛利托沃瑞利单抗致乙肝病毒再激活1例的药学监护
- Author:
Duohui LI
1
;
Jingyu XU
2
;
Lin LI
1
;
Qian ZHANG
1
;
Liqin TANG
3
;
Yingqi WU
3
Author Information
1. Dept. of Pharmaceutical Administration，Anqing Municipal Hospital，Anhui Anqing 246003，China
2. Dept. of Pharmacy，Huaibei People’s Hospital，Anhui Huaibei 235000，China
3. Dept. of Pharmacy，the First Affiliated Hospital of University of Science and Technology of China （Anhui Provincial Hospital），Hefei 230001，China
- Publication Type:Journal Article
- Keywords:
iparomlimab and tuvonralimab;
cervical cancer;
hepatitis B virus reactivation;
adverse reactions;
pharmaceutical
- From:
China Pharmacy
2025;36(24):3113-3117
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To report a case of hepatitis B virus （HBV） reactivation induced by iparomlimab and tuvonralimab， summarize the clinical characteristics and potential mechanisms of such adverse reactions induced by immune-checkpoint inhibitors （ICIs）， and provide references for clinical application. METHODS From the perspective of a clinical pharmacist， a retrospective analysis was conducted on the treatment course of a patient with metastatic cervical cancer who experienced HBV reactivation after receiving iparomlimab and tuvonralimab. Additionally， an analysis of the correlation with adverse reactions was performed， and the clinical characteristics， risk factors， potential mechanisms， key points of treatment approaches and pharmaceutical care associated with HBV reactivation induced by ICIs were summarized. RESULTS & CONCLUSIONS The patient developed HBV reactivation and severe liver injury after using iparomlimab and tuvonralimab. The condition improved following drug discontinuation， and symptomatic treatment such as glucocorticoids. According to Naranjo’s Assessment Scale and China’s Measures for the Reporting and Monitoring of Adverse Drug Reactions， the association between iparomlimab and tuvonralimab and HBV reactivation was judged as “highly probable”， and it was identified as a new adverse reaction； the correlation between iparomlimab and tuvonralimab， paclitaxel and liver injury was “highly probable”. HBV reactivation in hepatitis B patients receiving standardized antiviral therapy is very rare after ICIs treatment； HBV reactivation is related to the overactivation of the immune system and disruption of immune balance induced by ICIs. For such patients， glucocorticoids should be administered for treatment， accompanied by pharmaceutical care， including pre- medication risk assessment and monitoring of relevant indicators during treatment.
